Invitation to presentation of Orexo´s Full Year Report 2022, incl. Q4

Uppsala, Sweden – January 18, 2023 – As previously communicated Orexo will announce the Full Year Report 2022, focusing on the development in the fourth quarter, on January 26 at 8 am CET.

The same day at 2 pm, analysts, investors, and media are invited to attend a presentation where Nikolaj Sørensen, CEO, and Fredrik Järrsten, CFO, will present the latest development and host a Q&A.

To attend via teleconference where you can ask questions verbally use this link: 
https://conference.financialhearings.com/teleconference/?id=5003429
When registered you will be provided with phone numbers and a conference ID to access the conference.

To attend via webcast:
https://ir.financialhearings.com/orexo-q4-2022

Prior to the event the presentation material will be available on the website under Investors/Reports, Presentations

For further information, please contact:

Orexo AB (publ.)
Lena Wange, IR & Communications Director
Tel: +46 (0)18 780 88 00
Email: ir@orexo.com

About Orexo

Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental health. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercializes its lead product ZUBSOLV® for treatment of opioid use disorder. Total net sales for 2021 amounted to SEK 565 million and the number of employees was 121. Orexo is listed on the Nasdaq Stockholm Main List (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities are performed.

For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube.